Newsroom

THE WOODLANDS, Texas--(BUSINESS WIRE)--Trecora has acquired the assets of Deltech Monomers OpCo LLC, located in Baton Rouge, Louisiana. The acquired facility is North America’s leading producer of divinyl benzene, vinyl toluene, and various other specialty monomers and will be part of Trecora’s Specialty Chemicals business headquartered in The Woodlands, TX. Trecora, a portfolio company of Balmoral Funds, is North America's leading producer of high purity hydrocarbons, specialty waxes and addit...

SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed an amended registration statement on Form F-4 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) that includes a management circular/prospectus and other relevant documents related to various proposals contained therein, and that the Registration Statement has been decla...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 3,600 shares of the Company’s common stock at an exercise price per share of $25.80, which was the clo...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516) informe qu’un troisième document en réponses aux questions reçues de la part des actionnaires est disponible sur le site Internet de la Société, dans la section « Investisseurs », « Info des actionnaires », « Documentation ». Ce nouveau document synthétise trois autres thématiques soulevées par les actionnaires à l’occasion du webinaire du 26 novembre 2025 : Business Development Financements Assemblée Gén...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Beren Therapeutics P.B.C.®, a Public Benefit Corporation and parent company of Mandos LLC®, today announced that Mandos received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for adrabetadex, an investigational drug for infantile-onset Niemann-Pick disease type C (NPC). BTD is granted by the FDA to expedite the development of drugs for serious or life-threatening conditions when preliminary clinical evidence may i...

サウスレイク（テキサス州）および ヨクネアム（イスラエル）--(BUSINESS WIRE)--（ビジネスワイヤ） -- アクティブな血管内デバイスの主要な開発企業である Rapid Medical™ は、急性虚血性脳卒中における末梢中血管閉塞（DMVO）患者を対象に、TIGERTRIEVER 13™ デバイスを評価する多施設ランダム化試験である DISTALS 試験において、患者登録が完了したことを発表しました。 「DMVO の脳卒中は虚血性脳卒中の最大 40％を占め、重大な障害を引き起こす可能性がありますが、その治療はこれまで不確実なままでした。ESCAPE-MEVO と DISTAL の最近の中立的な結果が示したのは 1 つの明確な点です――末梢の血栓除去には、末梢血管向けに特別に設計されたデバイスと試験が必要であるということです」と、カリフォルニア州 UCLA の DISTALS 主任研究者である Jeffrey Saver 医師は述べました。「TIGER 13 と DISTALS は、そのための専用設計を提供します。登録完了は、これらの患者ケアを本当に進展させうるエビデンス...

SOUTHLAKE, Texas & YOKNEAM, Israël--(BUSINESS WIRE)--Rapid Medical™, een toonaangevende ontwikkelaar van actieve endovasculaire hulpmiddelen, kondigt de voltooiing aan van de inschrijving van patiënten voor de DISTALS-studie, een multicenter gerandomiseerde studie ter evaluatie van het TIGERTRIEVER 13™-hulpmiddel bij patiënten met distale vaatocclusies (DMVO) bij een acute ischemische beroerte. "DMVO-beroertes vertegenwoordigen tot 40% van de ischemische beroertes en kunnen aanzienlijke invalid...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--ExaGrid®, de enige gelaagde back-upopslagoplossing in de branche met AI-gestuurde retentietijdvergrendeling (RTL) met een niet-netwerkgerichte laag (gelaagde air-gap), Auto Detect & Guard, vertraagde verwijderingen en onveranderlijkheid voor ransomwareherstel, heeft vandaag aangekondigd dat het bedrijf drie prijzen heeft gewonnen tijdens de 1e jaarlijkse MSP Channel Awards-ceremonie, gehouden in Londen op 3 december 2025, waaronder: Backup & DR Innov...

DENVER--(BUSINESS WIRE)--Rivalry Capital Launches as Next-Generation Private Equity Firm Focusing on Healthcare Transformation...

SOUTHLAKE, Texas e YOKNEAM, Israele--(BUSINESS WIRE)--Rapid Medical™, un importante sviluppatore di dispositivi endovascolari attivi, annuncia la conclusione dell'arruolamento di pazienti nello studio clinico multicentrico, randomizzato DISTALS, volto a valutare il dispositivo TIGERTRIEVER 13™ in pazienti con occlusioni vascolari distali di calibro medio (DMVO) nell'ictus ischemico acuto. “Gli ictus di tipo DMVO rappresentano fino al 40% dei casi di ictus ischemico e possono causare una disabil...